Skip to main content

Riggs Rory B's Form 4 filing

Royalty Pharma plc (RPRX) · filed Aug 11, 2022

Accession no.
0000899243-22-028395
Filed
Aug 11, 2022
Trade date
Aug 9, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market sales total $1.97M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Riggs Rory BCIK 0001016835Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2022Class A Ordinary SharesSSaleDisposed−45,000$43.73F1−$1,967,850376,712Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.66 to $43.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit List - Exhibit 24.1 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)